China Jo-Jo Drugstores Reports Fiscal Year 2023 Financial Results

China Jo-Jo Drugstores Reports Fiscal Year 2023

HANGZHOU, China, June 15, 2023 /PRNewswire/ --

China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online

and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced

its financial results for the fiscal year ended March 31, 2023.

Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores,

commented, "During the past fiscal year, we continued to provide high-quality services and products to our customers despite the

challenging and uncertain market environment. I would like to thank our entire team for their collective efforts and dedication. In the

new fiscal year, we are focusing on implementing strategic expansion initiatives to drive our growth including optimizing distribution

channels, attracting new customers and enhancing our brand recognition. To further complement our expansion, the continued innovation

of our business model and digital transformation remains at the forefront of our business. In addition, we expect to improve our operational

efficiency and manage our costs effectively. We remain dedicated to our commitment to creating value for our customers by enriching our

product portfolio and providing healthcare services to meet their evolving demand. We believe our concrete advantages in offering diversified

product selections, delivering additional value to customers and extending sales network are powerful catalysts for a formidable presence

in the healthcare market in the future. We are confident that Jo-Jo Drugstores will keep making a positive impact in China's healthcare

market and the communities we serve. We are looking forward to another fruitful fiscal year and we will keep making efforts in generating

more value for our shareholders."

Fiscal Year 2023 Financial Highlights

Fiscal Year 2023 Financial Results

Revenue for the fiscal year ended March 31, 2023

was $148.81 million, compared to $164.39 million for the same period of last year.

Revenue from the retail drugstores business decreased

by $0.88 million, or 1.0%, to $83.35 million for the fiscal year ended March 31, 2023, from $84.23 million for the same period of last

year. After excluding the impact of exchange rate fluctuation, the actual retail drugstores sales increased by 5.6%. The actual increase

in retail drugstore sales was primarily due to continuous efforts in promoting non-National Healthcare Security Administration ("NHSA")

covered products, close cooperation with major suppliers, and contribution from the new store sales.

Revenue from the online pharmacy business increased

by $2.17 million, or 7.2%, to $32.39 million for the fiscal year ended March 31, 2023, from $30.22 million for the same period of last

year. The increase was primarily caused by an increase in sales via e-commerce platforms such as Tmall. The Company maintained a membership

care program targeted at chronic disease customers. The Company has closely interacted with members via WeChat by providing healthcare

knowledge and reminding customers to refill medicine. By implementing a personalized customer care program, the Company was able to promote

sales. Additionally, the Company increasingly cooperates with certain

manufacturers to promote their products such as Dendrobium Candidum. These manufacturers reward the Company with lower supply prices and

more advertising supports. As a result, the Company is able to better promote sales.

Prescription drugs used to be prohibited from

sales online due to safety concern. However, as the government of mainland China has lifted the ban order, online prescription drug sales

become popular. As a result, the sale of prescription drugs was $10.61 million in the year ended March 31, 2023, as compared to $10.33

million in the year ended March 31, 2022.

Revenue from the wholesale business decreased

by $16.86 million, or 33.8%, to $33.08 million for the fiscal year ended March 31, 2023, from $49.94 million for the same period of last

year. As a relatively small wholesale distributor in pharmaceutical products, the Company's sales are subject to significant variance.

Wholesale business usually carries low gross profit margin. However, we incurred labor, logistic and tax cost for our wholesale business.

As a result, to keep reasonable profitability, we abandoned certain wholesales at low gross profit margin in the year ended March 31,

2023. As a result, the wholesale revenue declined.

Gross profit and gross margin

Total cost of goods sold decreased by $13.34 million,

or 10.4%, to $114.53 million for the fiscal year ended March 31, 2023, from $127.87 million for the same period of last year. Gross profit

decreased by $2.24 million, or 6.1%, to $34.28 million for the fiscal year ended March 31, 2023 from $36.52 million for the same period

of last year. Overall gross margin increased by 0.8 percentage points to 23.0% for the fiscal year ended March 31, 2023, from 22.2% for

the same period of last year, due to higher retail drugstores profit margins.

Gross margins for retail drugstores, online pharmacy

and wholesale were 32.2%, 12.0%, and 10.9%, respectively, for the fiscal year ended March 31, 2023, compared to gross margins for retail

drugstores, online pharmacy and wholesale of 32.0%, 11.9%, and 12.0%, respectively, for the same period of last year.

Loss from operations

Selling expenses decreased by $1.70 million, or

5.5%, to $29.18 million for the fiscal year ended March 31, 2023 from $30.88 million for the same period of last year. The decrease in

selling expenses was primarily due to decrease in rent, partially offset by increase in the sales and marketing expenses.

General and administrative expenses increased

by $7.48 million, or 91.4%, to $15.67 million for the fiscal year ended March 31, 2023 from $8.19 million for the same period of last

year. The increase in general and administrative expenses was primarily due to the increase in bad debt expense. Such expenses as a percentage

of revenue increased to 10.5% from 5.0% for the same period a year ago. In the year ended March 31, 2023, the Company recorded an increase

in the allowance for bad debts of $7.58 million as compared to the increase in the allowance for bad debts of $1.32 million in the fiscal

year ended March 31, 2022.

The Company recorded share based compensation

of $10.36 million and $0 for the years ended March 31, 2023 and 2022. In April and December 2022, the Company issued a total of 3,000,000

ordinary shares and recorded share-based compensation of approximately $10.36 million.

The Company recorded an impairment of long-lived

assets of $0 and $0.15 million for the year ended March 31, 2023 and 2022. In the year ended March 31, 2023, the Company evaluated the

forest land use rights and did not record an impairment. In the year ended March 31, 2022, the Company evaluated the forest land use rights

and recorded an impairment of $0.15 million.

Loss from operations was $20.93 million for the

fiscal year ended March 31, 2023, compared to $2.69 million for the same period of last year. Operating margin was (14.1)% and (1.6)%

for the fiscal year ended March 31, 2023 and 2022, respectively.

Net loss was $21.14 million, or $2.07 per basic

and diluted share for the fiscal year ended March 31, 2023, compared to net loss of $3.20 million, or $0.92 per basic and diluted share

for the same period of last year.

As of March 31, 2023, the Company had cash of

$18.81 million, compared to $18.46 million as of March 31, 2022. Net cash used in operating activities was $3.28 million for the fiscal

year ended March 31, 2023, compared to $5.39 million for the same period of last year. The change is primarily attributable to a decrease

in cash provided by inventories and biological assets of $2.05 million, a decrease in cash provided by customer deposits of $1.71 million,

a decrease in cash due to net loss of $17.94 million offset by an increase of $10.36 million in stock compensation, an increase in cash

provided by accounts payable of $5.32 million. Net cash used in investing activities was $0.32 million for the fiscal year ended March

31, 2023, compared to $0.31 million for the same period of last year. The change is primarily attributable to purchases of long term assets.

Net cash provided by financing activities was $2.37 million for the fiscal year ended March 31, 2023, compared to $4.84 million for the

same period of last year. The change is primarily due to repayment of notes payable and proceeds from equity financing such as private

placement and debt financing.

As of March 31, 2023, the Company had a working

capital deficit of $2.1 million, a net loss of approximately $21.1 million and net cash used in operating activities of $3.3 million.

These factors raise substantial doubt about its ability to continue as a going concern. However, non-cash expenses such as stock-based

compensation, bad debt direct write-off and provision, and investment loss accounts for approximately $10.4 million, $7.6 million and

$2.3 million respectively. Excluding these non-cash expenses, the net loss is approximately $0.8 million.

In August and October 2022 the Company raised

capital by issuing ordinary shares to private investors for a total proceeds of $4.7 million. In January 2023, the Company closed a registered

direct offering with gross proceeds of $2.6 million from its effective shelf registration statement.

The Company has a credit line agreement from a

local bank as described in detail in Note 16 of its annual report on Form 20-F to be filed the date hereto. As of March 31, 2023, approximately

$0.29 million of the aforementioned bank credit line was available for further borrowing. As the economy growth slows down, the national

interest continues to decrease. Local banks are encouraged to provide low interest rate loans to local enterprises.